Mobilization of rat stomach ECL-cell histamine in response to short- or long-term treatment with omeprazole and/or YF 476 studied by gastric submucosal microdialysis in conscious rats.
1. Mobilization of histamine from the ECL cells was monitored by gastric submucosal microdialysis in conscious rats. The ECL cells are known to operate under gastrin control and the purpose of the present study was to examine their in situ response to short-term (12 h) as well as long-term (28 days) hypergastrinaemia, induced by treatment with the proton pump inhibitor omeprazole. 2. Hypergastrinaemia promptly raised the histamine concentration in the microdialysate. The effect was prevented by CCK(2) receptor blockade (YF476). On day 7 of omeprazole treatment the microdialysate histamine concentration reached a peak, five times higher than before treatment. Subsequently (14 and 28 days), less histamine was mobilized. 3. Gastrin infusion (4 h) raised the microdialysate histamine concentration in a dose-dependent manner in fasted rats and freely fed rats and in rats treated with omeprazole for a week. However, while fasted and fed rats responded to low doses of gastrin, the omeprazole-treated rats required large doses of gastrin to respond. 4. When the amount of histamine mobilized was related to the serum gastrin concentration the following EC(50) values could be calculated: fasted rats 2.3 x 10(-10) M, freely fed rats 2.5 x 10(-10) M, omeprazole-treated rats 8.7 x 10(-10) M. The maximal histamine responses in the three groups were 18.4 pmol 4 h(-1)+/-0.8, 21.9 pmol 4 h(-1)+/-1.2 and 68.0 pmol 4 h(-1)+/-3.5, respectively. 5. The results suggest that ECL cells, exposed to a high gastrin concentration for a week, respond with a shift in the receptor-ligand binding affinity from high to low. Apparently, CCK(2) receptors of the ECL cells are subject to dynamic changes with respect to ligand-binding affinity.
Konagaya
T
T
Department of Pharmacology, Institute of Physiological Sciences, University of Lund, Sölvegatan 10, S-223 62 Lund, Sweden.
Bernsand
M
M
Norlén
P
P
Håkanson
R
R
D000818:Animals; D001570:Benzodiazepinones / Q000008:administration & dosage / Q000494:pharmacology*; D003243:Consciousness; D004305:Dose-Response Relationship, Drug; D019861:Enterochromaffin-like Cells / Q000187:drug effects* / Q000378:metabolism*; D005215:Fasting; D005753:Gastric Mucosa / Q000166:cytology / Q000187:drug effects* / Q000378:metabolism; D005755:Gastrins / Q000097:blood / Q000494:pharmacology; D006632:Histamine / Q000378:metabolism; D006636:Histamine Release / Q000187:drug effects*; D006727:Hormone Antagonists / Q000008:administration & dosage / Q000494:pharmacology; D006801:Humans; D008297:Male; D017551:Microdialysis; D009853:Omeprazole / Q000008:administration & dosage / Q000494:pharmacology*; D010671:Phenylurea Compounds / Q000008:administration & dosage / Q000494:pharmacology*; D054328:Proton Pump Inhibitors; D051381:Rats; D017207:Rats, Sprague-Dawley; D011949:Receptors, Cholecystokinin / Q000037:antagonists & inhibitors / Q000378:metabolism; D013997:Time Factors
D001570:Benzodiazepinones; D005755:Gastrins; D006727:Hormone Antagonists; D010671:Phenylurea Compounds; D054328:Proton Pump Inhibitors; D011949:Receptors, Cholecystokinin; D006632:Histamine; C104428:YF 476; D009853:Omeprazole